Levosulpiride Ferrer

Levosulpiride, the active ingredient in Levosulpiride Ferrer, is a benzamide antipsychotic presented as a pharmaceutical preparation for oral, intramuscular and intravenous use. It is employed in the management of schizophrenia, depressive disorders and functional dyspepsia in adult patients.

GNH USA supplies Levosulpiride Ferrer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levosulpiride acts on dopaminergic pathways and is indicated for several psychiatric and gastrointestinal conditions.

- Schizophrenia: helps reduce positive symptoms such as hallucinations and delusions. - Depressive disorders: may augment antidepressant therapy by improving mood and motivation. - Functional dyspepsia: alleviates upper‑gastrointestinal discomfort through its prokinetic activity.

Levosulpiride may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient light‑headedness, especially on standing. - Headache: occasional tension‑type headache. - Insomnia: difficulty initiating or maintaining sleep. - Extrapyramidal symptoms: mild tremor or rigidity. - Hyperprolactinemia: increased prolactin levels causing breast tenderness.

Serious or Rare Side Effects: - Tardive dyskinesia: persistent involuntary movements. - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - QT interval prolongation: risk of cardiac arrhythmia. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatotoxicity: abnormal liver enzymes indicating liver injury. - Agranulocytosis: dangerously low white‑blood‑cell count.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

- Extrapyramidal monitoring: assess for tremor, rigidity or abnormal movements. - Cardiac assessment: obtain baseline ECG if patient has cardiac risk factors. - Liver function: check hepatic enzymes in patients with hepatic impairment. - Elderly caution: start with lower doses and monitor for confusion or falls. - Discontinuation: taper gradually to avoid withdrawal or rebound symptoms. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levosulpiride can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: may precipitate hypertensive crisis. - Other dopamine antagonists: increase risk of extrapyramidal symptoms. - QT‑prolonging agents: additive risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors: may raise levosulpiride plasma concentrations. - Anticholinergic drugs: can mask anticholinergic side effects. - Alcohol: may enhance sedation and dizziness.